What is Lumos Pharma, Inc. (LUMO) stock price today?

Lumos Pharma, Inc. (LUMO) is currently trading at $4.34, up 0% today.

What is LUMO P/E ratio?

Lumos Pharma, Inc.'s P/E ratio is -1.04. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is LUMO return on equity (ROE)?

Lumos Pharma, Inc.'s return on equity (ROE) is -78.34%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Lumos Pharma, Inc.'s market cap?

Lumos Pharma, Inc. has a market capitalization of $37.54M.

NASDAQ · Biotechnology

Lumos Pharma, Inc. (LUMO) Stock

$4.34 +0.00% NASDAQ: LUMO Healthcare

Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions.

Valuation

Metric	Value
Price	$4.34
Market Cap	$37.54M
P/E Ratio	-1.04
P/B Ratio	1.29
P/S Ratio	18.30
EPS (TTM)	$-4.18
52-Week High	$4.58
52-Week Low	$1.37
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-78.34%
ROA	-83.75%
ROCE	-108.94%
Gross Margin	100.00%
Operating Margin	-1850.00%
Net Margin	-1700.00%
Debt/Equity	0.02
Current Ratio	5.69

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$1.0M	$0	$0	$2.0M	$2.0M
Operating Profit	$-45.0M	$-26.0M	$-31.0M	$-32.0M	$-37.0M
Net Profit	$-43.0M	$-6.0M	$-30.0M	$-31.0M	$-34.0M
EPS	$-10.39	$-0.84	$-3.65	$-3.71	$-4.18
Op Margin	-4822.0%	-15656.5%	-13629.1%	-2103.7%	-1785.2%

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$97.0M	$129.0M	$100.0M	$72.0M	$41.0M
Total Liabilities	$18.0M	$12.0M	$11.0M	$13.0M	$13.0M
Cash	$91.0M	$99.0M	$95.0M	$56.0M	$35.0M
Borrowings	$1.0M	$0	$1.0M	$0	$1.0M

Latest News

Is McCormick’s (MKC) Black Currant Menu Push a Subtle Bet on Brand-Led Growth? Simply Wall St. · Aug 8, 2026 7 Reasons Pershing Square (PS) Looks Pricey After Ackman Spotlighted AI Holdings Simply Wall St. · Aug 8, 2026 Will AI-Driven Advanced Packaging and Record Q2 Results Reshape Nova’s (NVMI) Investment Narrative? Simply Wall St. · Aug 8, 2026 Sharplink (SBET) Looks Pricey Following Earnings That Put Growth And Losses In Focus Simply Wall St. · Aug 8, 2026 Is Rolls-Royce Holdings (LSE:RR.) Fully Valued After Buybacks, Half Year Results And A Dividend Increase? Simply Wall St. · Aug 8, 2026

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$-30.0M	$-23.0M	$-30.0M	$-27.0M	$-31.0M
Investing Cash Flow	$0	$117.0M	$26.0M	$-23.0M	$11.0M
Financing Cash Flow	$0	$0	$0	$-1.0M	$-1.0M
Net Cash Flow	$-30.0M	$94.0M	$-4.0M	$-39.0M	$-21.0M
Free Cash Flow	$-30.0M	$-23.0M	$-30.0M	$-27.0M	$-31.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.09
EV / EBITDA	-0.08
FCF Yield	-82.84%
Quick Ratio	5.69
Interest Coverage	—
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CERCCerecor Inc.	$2.93	-1.68%	-0.53	$38.63M	0.00%
EYENEyenovia, Inc.	$7.56	+3.99%	-1.14	$38.59M	0.00%
GRCEGrace Therapeutics, Inc.	$1.89	-5.03%	-1.64	$30.76M	0.00%
IRDOpus Genetics, Inc.	$4.10	-3.30%	-3.23	$341.10M	0.00%
LIANYLianBio	$0.07	-12.50%	1.56	$7.64M	6.14%

About Lumos Pharma, Inc.

Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions. The company's operations are based in Austin, Texas.

Lumos Pharma, Inc. is headquartered in US.

Lumos Pharma, Inc. (LUMO) stock trades at $4.34 with a market capitalization of $37.54M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.04, reflecting a net loss over the last twelve months, price-to-book of 1.29, price-to-sales of 18.30. Over the past 52 weeks the stock has ranged between $1.37 and $4.58, and currently trades 5.2% below its 52-week high.

On profitability, Lumos Pharma, Inc. generates a return on equity (ROE) of -78.34% (negative, reflecting a net loss), return on capital employed of -108.94%, an operating margin of -1850.00%, a net profit margin of -1700.00%.

Official website: www.lumos-pharma.com